EP 3571227 A1 20191127 - ANTI-TGF-BETA ANTIBODIES AND THEIR USE
Title (en)
ANTI-TGF-BETA ANTIBODIES AND THEIR USE
Title (de)
ANTI-TNF-BETA-ANTIKÖRPER UND DEREN VERWENDUNGEN
Title (fr)
ANTICORPS ANTI-TGF-BÊTA ET LEUR UTILISATION
Publication
Application
Priority
- EP 17305061 A 20170120
- IB 2018000088 W 20180119
Abstract (en)
[origin: WO2018134681A1] The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
IPC 8 full level
C07K 16/22 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC (source: EA EP US)
A61P 35/00 (2017.12 - EA EP US); C07K 16/22 (2013.01 - EA EP US); C07K 16/2818 (2013.01 - EA EP US); C07K 16/30 (2013.01 - EA US); A61K 2039/505 (2013.01 - EA EP US); A61K 2039/507 (2013.01 - EA EP US); C07K 2317/52 (2013.01 - EA US); C07K 2317/56 (2013.01 - EA US); C07K 2317/565 (2013.01 - EA US); C07K 2317/76 (2013.01 - EA US); C07K 2317/92 (2013.01 - EA EP US)
Citation (search report)
See references of WO 2018134681A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2018134681 A1 20180726; WO 2018134681 A8 20190815; WO 2018134681 A8 20191010; EA 201991729 A1 20191230; EP 3571227 A1 20191127
DOCDB simple family (application)
IB 2018000088 W 20180119; EA 201991729 A 20180119; EP 18711394 A 20180119